Report Code: A14445 | Pages: NA | Mar 2023 | 732 Views | ||
Author(s) : NA | Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Menkes Syndrome Market
Request Now !Menkes syndrome is essentially a rare, X-linked genetic disorder of copper metabolism, which is caused by gene mutations of copper transporter ATP7A that disrupts the copper levels in the body and makes it hard for the body to properly distribute the copper throughout the body. Thus, the brain and other body parts have deficiency of copper while the small intestine and kidneys have a buildup of copper. Even infants when affected by this disease get jaundice due to the excessive bilirubin in their blood known as hyperbilirubinemia. This disease is primarily characterized by dry skin, failure to gain weight, and sparse or kinky hair, which is white or grey in color.
What is the Impact of COVID-19 Pandemic on the Menkes Syndrome Market?
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the menkes syndrome market.
Top Impacting Factors
Market Trends
New Product Launches to Flourish the Market
In 2020, Cyprium Therapeutics, Inc., a Fortress Biotech partner company, announced the launch of CUTX-101, a subcutaneous injectable formulation of Copper Histidinate, which helps to restore copper homeostasis, and maintaining serum copper levels in the normal age-appropriate range.Â
Key Benefits of the Report
Questions Answered in the Menkes Syndrome Report
Menkes Syndrome Market Report Highlights
Aspects | Details |
---|---|
By Drug Class |
|
By Application |
|
By End Users |
|
By Region |
|
Key Market Players | Fortress Biotech, Teva Pharmaceutical Industries Ltd, Amerigen Pharmaceuticals Limited, Mylan N.V, Bausch Health, H. Lundbeck A/S |
Loading Table Of Content...
Start reading.
This Report and over 19,654+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers